#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Combination of sofosbuvir and velpatasvir (Epclusa®)


Authors: P. Urbánek
Authors‘ workplace: Interní klinika 1. LF UK a ÚVN Praha
Published in: Gastroent Hepatol 2016; 70(6): 553-554
Category: Drug Profile


Sources

1. SPC Epclusa®, Datum první registrace: 6. července 2016, datum poslední revize textu: červenec 2016.

2. Younos­si ZM, Stepanova M, Feld J et al. Sofosbuvir/ velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-control­led trial. J Hepatol 2016; 65(1): 33– 39. doi: 10.1016/j.jhep.2016.02.042.

3. Younos­si ZM, Stepanova M, Sulkowski Met al. Ribavirin-free regimen with sofosbuvir and velpatasvir is as­sociated with high ef­ficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from ASTRAL-2 and -3 clinical trials. Clin Infect Dis 2016; 63(8): 1042– 1048. doi: 10.1093/cid/ciw496.

4. Foster GR, Afdhal N, Roberts SK et al. Sofosbuvir and velpatasvir for HCV genotype 2and 3 infection. N Engl J Med 2015; 373(27): 2608– 2617. doi: 10.1056/ NEJMoa1512612.

5. Cur­ry MP, O’Leary JG, Bzowej N et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cir­rhosis. N EnglJ Med 2015; 373(27): 2618– 2628. doi: 10.1056/NEJMoa1512614.

Labels
Paediatric gastroenterology Gastroenterology and hepatology Surgery

Article was published in

Gastroenterology and Hepatology

Issue 6

2016 Issue 6

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#